Key result
Pericardial effusion in hospitalized COVID-19 patients was associated with excess mortality (nonadjusted HR 2.44, P=0.0005), though this was marginal after multivariate adjustment (HR 1.86, P=0.06).
Why the study?
The scope of pericardial involvement in COVID-19 infection was unknown.
Observational (n=530)
Hazard Ratio: 1.86
p-value: p=0.06
May signal higher COVID-19 mortality risk but weakens after adjustment; leaves open independent prognostic value.
Background The scope of pericardial involvement in COVID‐19 infection is unknown. We aimed to evaluate the prevalence, associates, and clinical impact of pericardial involvement in hospitalized patients with COVID‐19. Methods and Results Consecutive patients with COVID‐19 underwent clinical and echocardiographic examination, irrespective of clinical indication, within 48 hours as part of a prospective predefined protocol. Protocol included clinical symptoms and signs suggestive of pericarditis, calculation of modified early warning score, ECG and echocardiographic assessment for pericardial effusion, left and right ventricular systolic and diastolic function, and hemodynamics. We identified predictors of mortality and assessed the adjunctive value of pericardial effusion on top of clinical and echocardiographic parameters. The study included 530 patients. Pericardial effusion was found in 75 (14%), but only 17 patients (3.2%) fulfilled the criteria for acute pericarditis. Pericardial effusion was independently associated with modified early warning score, brain natriuretic peptide, and right ventricular function. It was associated with excess mortality (hazard ratio [HR], 2.44; P =0.0005) in nonadjusted analysis. In multivariate analysis adjusted for modified early warning score and echocardiographic and hemodynamic parameters, it was marginally associated with mortality (HR, 1.86; P =0.06) and improvement in the model fit ( P =0.07). Combined assessment for pericardial effusion with modified early warning score, left ventricular ejection fraction, and tricuspid annular plane systolic excursion was an independent predictor of outcome (HR, 1.86; P =0.02) and improved model fit ( P =0.02). Conclusions In hospitalized patients with COVID‐19, pericardial effusion is prevalent, but rarely attributable to acute pericarditis. It is associated with myocardial dysfunction and mortality. A limited echocardiographic examination, including left ventricular ejection fraction, tricuspid annular plane systolic excursion, and assessment for pericardial effusion, can contribute to outcome prediction.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an observational in COVID-19 (n=530). Pericardial effusion vs. No pericardial effusion was evaluated on Mortality (HR 1.86, p=0.06). Pericardial effusion in hospitalized COVID-19 patients was associated with excess mortality (nonadjusted HR 2.44, P=0.0005), though this was marginal after multivariate adjustment (HR 1.86, P=0.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: